Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$376M |
| 2 |
AGN
Allergan plc
AGN
|
+$262M |
| 3 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$213M |
| 4 |
HSP
HOSPIRA INC
HSP
|
+$179M |
| 5 |
SIAL
SIGMA - ALDRICH CORP
SIAL
|
+$160M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$531M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$460M |
| 3 |
SWY
SAFEWAY INC
SWY
|
+$318M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$258M |
| 5 |
ROC
ROCKWOOD HLDGS INC
ROC
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.56% |
| 2 | Healthcare | 10.46% |
| 3 | Industrials | 10.4% |
| 4 | Technology | 9.5% |
| 5 | Communication Services | 8.84% |
Similar funds
Thomas Steyer's Q1 2015 Portfolio in Review
As of Q1 2015, Thomas Steyer held 120 positions worth $6.85B, down 6.6% from $7.33B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Thomas Steyer withdrew a net $845M in Q1 2015, closing 27 positions and reducing 18 holdings. Its most notable exit was Allergan Inc, an estimated $531M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 16% of assets, up from 13% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Thomas Steyer opened a new position in PHARMACYCLICS INC worth $498M.
- Thomas Steyer's largest Q1 2015 buy was PHARMACYCLICS INC: 1,945,000 shares worth $498M.
- Thomas Steyer added most to Allergan plc in Q1 2015, an estimated $262M increase.
- Thomas Steyer's biggest Q1 2015 reduction was Coca-Cola Europacific Partners, cutting an estimated $123M.
- Thomas Steyer fully exited Allergan Inc in Q1 2015, selling an estimated $531M.
- Thomas Steyer's ten largest holdings make up 41% of its $6.85B portfolio in Q1 2015.
- Thomas Steyer opened 33 new positions and closed 27 in Q1 2015.
- Thomas Steyer's portfolio value fell 6.6% quarter-over-quarter to $6.85B.
Based on Farallon Capital Management's 13F filing for Q1 2015, filed 15 May 2015.